Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
193,828,463
-
Total 13F shares
-
117,300,177
-
Share change
-
+4,418,396
-
Total reported value
-
$3,824,660,106
-
Put/Call ratio
-
2.4%
-
Price per share
-
$32.61
-
Number of holders
-
114
-
Value change
-
+$145,729,688
-
Number of buys
-
72
-
Number of sells
-
32
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q2 2020
As of 30 Jun 2020,
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) was held by
114 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
117,300,177 shares.
The largest 10 holders included
Kohlberg Kravis Roberts & Co. L.P., VIKING GLOBAL INVESTORS LP, PERCEPTIVE ADVISORS LLC, VANGUARD GROUP INC, AMERICAN INTERNATIONAL GROUP INC, BlackRock Inc., HILLHOUSE CAPITAL ADVISORS, LTD., Aisling Capital Management LP, STATE STREET CORP, and Cormorant Asset Management, LP.
This page lists
114
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.